SEARCH · PubMed Health

Results for “HEART VALVES”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 577 records · Page 32Linked to original sources

PubMed2005

Heart valve cryopreservation: protocol for addition of dimethyl sulphoxide and amelioration of putative amphotericin B toxicity.

AIM: To investigate the need for stepwise addition of dimethyl sulphoxide to heart valves and amelioration of putative amphotericin B toxicity. METHODS: There were four groups: an untreated control (Group 1) and three experimental groups. For the latter, porcine heart valves were exposed to the antibiotic/antimycotic mixture used for disinfecting heart valves in the Bristol Heart Valve Bank, for 24 h at 22 degrees C. Dimethyl sulphoxide (Me2SO, 10% v/v) was added either in two steps (5% then 10%) (Group 2) or in a single step. For single-step addition, valves were either first placed in Hanks' balanced salt solution for 10 min before transfer to the cryoprotectant solution (Group 3) or immersed directly in the 10% cryoprotectant solution (Group 4). The valve leaflets were dissected from the valves and frozen in 10% Me2SO in multi-well tissue culture plates at 1 degrees C/min to -80 degrees C. After storage overnight, the valve leaflets were warmed at approximately 11 degrees C/min and the cryoprotectant was removed by single-step dilution in excess Hartmann's solution. Each leaflet was then divided into four pieces, which were placed in separate wells of a culture plate. Outgrowth of cells from the explants was monitored daily and graded according to the extent of cell growth. RESULTS: After freezing and thawing, only 77% of the explants from valves placed directly into 10% Me2SO (Group 4) showed outgrowth of cells after freezing compared with 89% with two-step addition of Me2SO (Group 2) and 95% with one-step addition after the extra rinse in Hanks' solution (Group 3) (chi2, p=0.001). 92% of unfrozen control explants showed outgrowth of cells (Group 1). Only 37% of Group 4 explants reached confluence compared with 63 and 56%, respectively, of Groups 2 and 3 explants (chi2, p=0.007). The rates of cell growth in Group 2 (two-step addition of Me2SO) and Group 3 (one-step addition of Me2SO with additional Hanks' solution rinse) were similar and faster than the Group 4 (one-step addition of Me2SO without the additional Hanks' rinse). CONCLUSION: Single-step addition of Me2SO before freezing gave similar results to two-step addition provided an additional rinse in Hanks' solution was introduced after exposure to the antibiotic/antimycotic mixture. This suggests that antibiotic/antimycotic carryover may have been harmful during freezing and that the additional rinse in Hanks before one-step addition of Me2SO, and the 5% Me2SO step in the two-step protocol, merely served to reduce this carryover.

Amphotericin B↗

PubMed1988

In vitro comparison of aortic heart valve prostheses. Part 1: Mechanical valves.

The hydrodynamic performance of a series of mechanical heart valve prostheses is measured in the aortic position. All experiments are performed in an electrohydraulic, computer-controlled pulse duplicator simulating the left side of the human circulatory system. Testing conditions are set according to a Food and Drug Administration interlaboratory comparison protocol with cardiac outputs of 3.0, 4.5, 6.5, and 8.0 L/min at a constant heart rate of 70 beats/min. Mean systolic pressure differences, volume losses, and energy losses, as well as dimensionless pressure losses and energy loss coefficients, are calculated from the recorded pressure, volume, and flow tracings. The results of 10 mechanical heart valve prostheses (eight tilting disc valves and two bileaflet valves) are presented and their clinical relevance is discussed.

Aortic Valve↗

PubMed2005

Bone marrow-derived myofibroblasts are present in adult human heart valves.

BACKGROUND AND AIM OF THE STUDY: Endothelial, smooth muscle and cardiomyocyte chimerism has been shown to occur in the human heart. It is currently unknown whether the bone marrow contributes to cellular components of adult human heart valves. Here, it was determined whether bone marrow-derived smooth muscle-like cells (SMLC) are present in the heart valves of adult subjects. METHODS: By combining immunofluorescence staining and fluorescence in-situ hybridization (FISH) for X and Y chromosomes, the heart valves of gender-mismatched bone marrow transplant patients were examined for the presence of chimeric cells expressing calponin, a smooth muscle-specific protein. Concomitant staining for CD68 antigen was carried out to exclude cells of a monocytic lineage. RESULTS: The mean percentage of bone marrow-derived SMLC in valves was 0.28 +/- 0.03%, with the total proportion of chimeric cells estimated at 0.71 +/- 0.05%. The mean proportion of CD68+ cells was 0.33 +/- 0.05%. Not a single cell stained doubly for calponin and CD68 antigen. CONCLUSION: These data establish, for the first time, human bone marrow as a source of progenitor cells contributing to SMLC in adult human heart valves.

Adult↗

PubMed2001

Lack of calcification of tissue engineered heart valves in juvenile sheep.

The presence of viable endothelial cells may support longer durability and the absence of calcification in valve prostheses. This study shows the development of a tissue engineered heart valve, constructed from viable autologous endothelial cells on an acellular matrix and its evaluation in juvenile sheep. In 3-month-old sheep (n = 8) a piece of vein was harvested to culture autologous endothelial cells. A porcine acellular matrix was reendothelialized and implanted in juvenile sheep as pulmonary interposition. The valves were explanted after 1 week, 3 and 6 months. Examination was performed by X-ray, light microscopy, and atomic absorption spectrometry. Reendothelialization mean rate was 10.3 x 10(5) cells/cm(2) with a mean endothelial cell viability of 95.5% (0.98 x 10(5) cells/cm(2)). X-ray examination showed no cusp calcification at 1 week, 3 and 6 months, which was confirmed by light microscopy. Immunostaining for factor VIII demonstrated colonization of viable mature autologous endothelial cells on the heart valve after the seeding process. The atomic absorption spectrometry showed no significant increase of the calcium content after 3 (P value >.1) and 6 months (P value >.1) compared with nonimplanted tissue engineered heart valves. The tissue engineered valve showed no cusp calcification in the juvenile sheep after 3 and 6 months.

Animals↗

PubMed2001

Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves.

1. Permanent therapy with oral anticoagulants offers the most consistent protection in patients with mechanical heart valves. 2. Antiplatelet agents alone do not consistently protect patients with mechanical prosthetic heart valves, including patients in sinus rhythm with St. Jude Medical valves in the aortic position. 3. Levels of oral anticoagulants that prolong the INR to 2.0 to 3.0 appear satisfactory for patients with St. Jude Medical bileaflet and Medtronic-Hall tilting disk mechanical valves in the aortic position, provided they are in sinus rhythm and the left atrium is not enlarged. Presumably, this is also true for the CarboMedics bileaflet valve, based on the observation of no clinically important difference in the rate of systemic embolism with this valve and the St. Jude Medical bileaflet valve. 4. Levels of oral anticoagulants that prolong the INR to 2.5 to 3.5 are satisfactory for tilting disk valves and bileaflet prosthetic valves in the mitral position. 5. Experience in patients with caged ball valves who had prothrombin time ratios reported in terms of the INR is sparse, because few such valves have been inserted in recent years. The number of surviving patients with caged ball valves continues to decrease. It has been suggested that the most advantageous level of the INR in patients with caged ball or caged disk valves should be as high as 4.0 to 4.9. However, others have shown a high rate of major hemorrhage with an INR that is even somewhat lower, 3.0-4.5. The problem is self-limited, however, because few such valves are being inserted. 6. In patients with mechanical heart valves, aspirin, in addition to oral anticoagulants, has been shown to diminish the frequency of thromboemboli. The risk of bleeding is somewhat increased if the INR is 2.0 to 3.0 or 2.5 to 3.5. However, if the INR is 3.0 to 4.5, the risk of bleeding becomes excessive with aspirin. There are no investigations in which aspirin 80 mg/d in combination with oral anticoagulants was evaluated. 7. Data are insufficient to recommend dipyridamole over low doses of aspirin in combination with warfarin. Whether dipyridamole plus aspirin is more effective than aspirin alone when used with warfarin is undetermined. 8. Patients with bioprosthetic valves in the mitral position as well as patients with bioprosthetic valves in the aortic position may be at risk for thromboemboli during the first 3 months after operation. 9. Among patients with bioprosthetic valves in the mitral position, oral anticoagulants at an INR of 2.0 to 2.3 were as effective as an INR of 2.5 to 4.0 and were associated with fewer bleeding complications during the first 3 months after operation.10. Aspirin may reduce the long-term frequency of thromboembolism in patients with bioprosthetic valves.

Administration, Oral↗

PubMed2000

Does the Ross operation fulfil the objective performance criteria established for new prosthetic heart valves?

BACKGROUND AND AIM OF THE STUDY: Objective Performance Criteria (OPC) were established to compare a new heart valve prosthesis with fixed standards of linearized complication rates for morbid events: thromboembolism, thrombosis, hemorrhage, leakage and endocarditis. Although the pulmonary autograft operation provides optimal hemodynamic performances, the morbidity of both the autograft and homograft remain topics of controversy. METHODS: Valve-related morbid events and echocardiography in 109 patients who have undergone the Ross operation since 1991 were evaluated at annual follow up examination (mean 2.8 years; range: 1 month to 8 years). Linearized rates (number of events per 100 years patient exposure) were calculated to establish the safety and efficacy of this operation (288.7 years cumulative patient-years). RESULTS: Three patients died perioperatively (2.8%); two patients were reoperated due to autograft incompetence (1.8%, both valve repairs). No patient is currently on anticoagulation therapy, and no events of thromboembolism, valve thrombosis or bleeding were observed during follow up. Two patients had homograft endocarditis but were asymptomatic with moderate incompetence at the last follow up examination. There was no significant increase in aortic incompetence (AI) or pulmonary incompetence (PI) between discharge and follow up (AI, 0.4 +/- 0.5 versus 0.6 +/- 0.6; PI, 0.2 +/- 0.4 versus 0.4 +/- 0.6). In comparing the OPC (events per patient-year) for the Ross operation with those for tissue and mechanical valves, the results were: thromboembolism 0% (tissue 2.5%, mechanical 3%), valve thrombosis 0% (0.2% and 0.8%), all bleeding 0% (1.4% and 3.5%), major bleeding 0% (0.9% and 1.5%), all leakage 0.7% (1.2% and 1.2%), major leakage 0.7% (1.2% and 1.2%) and endocarditis 0.7% (1.2% and 1.2%). CONCLUSION: The pulmonary autograft procedure provides optimal hemodynamics and echocardiographic performance, and low valve-related complication rates; thus, the OPC for tissue and mechanical heart valve prostheses can be fulfilled by this technically demanding operation. These results confirm that the autograft is an ideal aortic valve replacement device.

Adolescent↗

PubMed1990

A two-dimensional finite element analysis of a bioprosthetic heart valve.

A finite element scheme has been developed using total Lagrangian techniques for the two-dimensional analysis of bioprosthetic heart valve leaflets undergoing large deformation. Two models of a leaflet, namely a radial and a circumferential slice, have been analysed. The attachment of the slice to the stent was simulated by progressive contact on a circular former and the coaptation of the leaflets in the centre of a heart valve by a straight line of contact. For the circumferential model, different initial configurations have been considered. The prolapse pressure under which the heart valve closes has been shown to be small in comparison with the normal pressure a heart valve sustains. The regions of the valve that are most heavily stressed are subjected to a strong component of bending. The amount is sensitive to the details of the boundary conditions and to the initial configuration of the valve. These observations are likely to be significant in the use of this kind of stress analysis to improve the design of this type of valve.

Bioprosthesis↗

PubMed1999

Is minimally invasive heart valve surgery a paradigm for the future?

During the past 5 years, there has been considerable progress in the development of less invasive techniques for heart valve surgery. Both aortic and mitral valve surgery can now be performed through small chest wall incisions. Recent evidence confirms patient benefit with minimally invasive heart valve surgery. Although several approaches can be used, a partial upper sternotomy offers several advantages for minimally invasive heart valve surgery.

Aortic Valve↗

PubMed2003

Indication of cavitation in mechanical heart valve patients.

BACKGROUND AND AIM OF THE STUDY: Cavitation may cause erosion of prosthetic heart valve material. The phenomenon has been extensively studied in vitro, and an association between the presence of cavitation bubbles and high-frequency pressure fluctuations (HFPF) has been established. In-vivo studies examining this phenomenon are scarce; hence, the study aim was to compare HFPF in patients with native, bioprosthetic or mechanical aortic valves, using both invasive and non-invasive measuring techniques. METHODS: Measurements were carried out in 16 patients implanted with a St. Jude Medical aortic valve; two control groups comprised 10 patients with normal aortic valves after coronary artery bypass surgery, and five patients implanted with a Carpentier-Edwards pericardial aortic bioprosthesis. HFPF were measured intraoperatively using a hydrophone placed near the aortic annulus, and postoperatively using the same hydrophone mounted in a specially designed water-filled sound chamber. The frequency spectrum was evaluated using Fast Fourier transformation, and the root mean square (RMS) value of the pressure signals was calculated in the frequency range 50-150 kHz. RESULTS: HFPF with intensities significantly above the noise floor were registered using both methods in the vicinity of mechanical heart valves. The RMS values of the HFPF for all three patient groups measured intra- and postoperatively disclosed a significant difference between the mechanical valves and the two control groups, indicating that there is no cavitation in the vicinity of the biological or the native valves. CONCLUSION: HFPF are present in the vicinity of mechanical aortic valves and can be measured in patients, both invasively and non-invasively. This indication of cavitation was not observed in patients with either native or bioprosthetic aortic valves.

Adult↗

PubMed2005

Quality of life after heart valve surgery with prolonged intensive care.

BACKGROUND: A small proportion of patients undergoing heart valve operations require prolonged intensive care after surgery. Little is known about the quality of life that such patients attain after hospital discharge. METHODS: All consecutive patients who underwent primary heart valve surgery from 1998 to 2003 and required 8 days or more of treatment in an intensive care unit (ICU) were included (n = 225). At follow-up on August 31, 2004, 154 of these patients were alive. A cohort (n = 154) matched for sex, age, type of procedure, and week of operation, with an uncomplicated postoperative course (ICU stay of 2 days or less), served as the control group. All patients received the Medical Outcomes Study Short-Form 36, the Nottingham Health Profile, and the Hospital Depression and Anxiety scale to evaluate their quality of life. RESULTS: Survival at 5 years in the total ICU group was 68% (154 of 225). According to SF-36, the ICU study cohort reported poorer physical health but equal mental health compared with controls. On the Nottingham Health Profile, the ICU group reported more problems in all domains except emotional reactions and sleep. There was no difference in anxiety or depression between the groups. The ICU patients were in more advanced New York Heart Association functional classes preoperatively and postoperatively. No patient in the ICU study cohort regretted undergoing the operation, and 80% experienced improvement after surgery. CONCLUSIONS: This study showed reduced quality of life in terms of physical health and equal mental health in patients who required prolonged intensive care after heart valve surgery compared with controls without complications.

Adult↗

PubMed1989

[Results of heart valve replacement: especially on the selection criteria for valve prostheses and on a new anticoagulation regimen].

Since March 1981 till the end of 1987, a total of 76 artificial heart valves were implanted in 72 patients. Heart valve prostheses were selected individually according to the patient's needs rather than assigning a single model to every patient. Postoperatively patients were placed on an anticoagulation therapy regimen consisting of reduced-dose warfarin (prothrombin time maintained at 30% of the control) and a small dose (81 mg/day) aspirin. During this period no bioprosthesis was implanted. For aortic valves, Starr-Edwards caged-ball valves were used in 53.1% and St. Jude Medical (SJM) valves in 37.5%. For mitral valves, SJM valves were used in 68%. No mechanical valve failure and no thrombosed valve was encountered. There was one patient-prosthesis missmatch. The incidence of thromboembolism for the entire series was 5/181.2 patient-years. There was 1-2/181.2 patient-years incidence of hemorrhagic complications. These figures were comparable to the ones with conventional warfarin therapy. No intracranial hemorrhage was encountered. Our selection criteria for artificial heart valves and our method of anticoagulation were discussed in detail. We conclude that at present there is no single prosthesis which satisfies all the varying needs of every patient, and the prosthesis which is best suited to that particular patient should be selected. We are generally happy with our current method of postoperative anticoagulation and will continue with this regimen.

Adult↗

PubMed1992

[The thrombosis service as a source of information for studies in patients with heart valve prostheses].

A new study design was evaluated for the estimation of the incidence of thromboembolic complications, bleeding complications and endocarditis in patients with prosthetic heart valves. Thromboembolism is a serious complication in patients with artificial heart valves. Consequently lifelong anticoagulation therapy is indicated for such patients. In the Netherlands the intensity of the anticoagulation is monitored by a network of regional anticoagulation services. The computerized patient information system of the Leiden anticoagulation service was used for a two year follow-up study of patients with mechanical heart valves. In these years anticoagulation was monitored in 273 patients with a total follow-up period of 442 patient-years. The incidence figures for thromboembolism, bleeding complications and endocarditis were 0.9/100 patient-years, 5.6/100 patient-years and 0.2/100 patient-years, respectively. The findings are similar to those of classical follow-up studies. This method is not suitable for detection of the direct early postoperative mortality or for follow-up of patient with heterografts. We conclude that the detection and follow-up by means of regional anticoagulation service offers an opportunity to investigate patients with mechanical heart valves in an efficient way without notable selection.

Actuarial Analysis↗

PubMed2006

Allogenic heart valve bank in the Department of Cardiovascular Surgery and Transplantology of Jagiellonian University in Cracow - 23 years experience in the treatment of aortic valve or aortic root diseases.

Allogenic aortic valves are widely used in case of native aortic valve or root disease as well as failed prosthetic valves with great success. At the Department of Cardiovascular Surgery and Transplantology of the Jagiellonian University in Cracow, aortic valve or aortic root replacement with allogenic aortic valve has been performed for 23 years. Allogenic heart valve bank was founded in 1980. In the bank we prepare both aortic allografts for adult cardiac surgical procedures and pulmonary allografts that are mostly used for repair of congenital heart disease.Allogenic aortic valves implantation was usually considered in our clinic for older patients, patients with infective endocarditis of the native or prosthetic valve, young women in reproductive age and patients with Marfan syndrome. Allografts exhibit excellent clinical performance and acceptable durability with no early failure if properly inserted. Between 1980 and 1992, allografts were obtained only from cadavers during routine autopsies. More than 10% of prepared allografts were exported to other cardiac surgery centres in Poland and foreign countries. Aortic valve replacement using allogenic aortic valves can be performed with acceptable mortality and good long-term results. The procedure although surgically more challenging has the advantage of not requiring anticoagulation therapy, hemodynamic performance of the allogenic valve is excellent, it demonstrates freedom from thromboembolism and infective endocarditis. We would like to emphasize the importance and advantages of the fact that allogenic heart valve bank is placed in the department of cardiovascular surgery and it is able to supply the department in heart valve allografts 24 h a day.

Adolescent↗

PubMed2006

Thrombolysis as first choice therapy in prosthetic heart valve thrombosis. A study of 68 patients.

BACKGROUND AND OBJECTIVES: Valvular thrombosis is a serious complication in patients with prosthetic heart valves. Traditional treatment is emergency surgery, but thrombolysis provides a non invasive alternative. In this paper we evaluate the efficacy and safety of thrombolysis in prosthetic heart valve thrombosis. METHODS: Data of 68 patients diagnosed of prosthetic valve thrombosis, treated at the Institute of Cardiology and Cardiovascular Surgery, Havana during a 6-years period were analyzed. They received thrombolysis with a recombinant streptokinase infusion at 250,000 IU in 30 minutes followed by 100,000 IU/hour during 72 hours or less if the thrombosis resolved before. The evaluation was based on clinical and echocardiographic findings. RESULTS: Affected sites were mitral (50 cases), tricuspid (9), and aortic (9). Mean time of prosthesis implantation was 6.8 years. The presentation form was generally heart failure (NYHA functional class III-IV) in 64 (94.1%) patients. Mean time interval between onset of symptoms and diagnosis was 10.6 days. There was total response to treatment in 58 (85.3%) patients, partial in 4 (5.9%) and failure in 6 (8.8%). Recombinant streptokinase overall dose was 5.1 x 10(6) IU and mean infusion time 50 hours. Major hemorrhagic complications were observed in two patients. Five embolic events occurred during thrombolysis. Four patients died. Rethrombosis was noted in 11 patients; 10 were retreated successfully with thrombolysis. CONCLUSIONS: Thrombolysis with recombinant streptokinase is efficacious and safe for the treatment of prosthetic heart valve thrombosis. It does not contraindicate surgical treatment if there is no total response, because patient goes to surgery in better hemodynamic conditions with lower risk. Nowadays it can be considered as first-line treatment in all patients with prosthetic heart valve thrombosis regardless of functional class unless specific contraindications exist.

Adolescent↗

PubMed2003

Black holes on MR images of the brain of patients with Björk-Shiley heart valves: additional observation in three cases.

We report the cases of three patients with Björk-Shiley convexo-concave heart valves with unusual black holes shown on cerebral MR images. For two patients, these findings were associated with fracture of the Björk-Shiley convexo-concave heart valve, and for the third, with worn surfaces on the heart valve. Susceptibility changes shown by MR imaging suggest the possibility that these black holes may be associated with microscopic metallic particles, although, the exact cause of these black holes remains undetermined.

Adult↗

PubMed1998

A comparison of the cavitation potential of prosthetic heart valves based on valve closing dynamics.

BACKGROUND AND AIMS OF THE STUDY: This study compares the cavitation potential of prosthetic heart valves based on valve closing dynamics. METHODS: A laser sweeping technique measured valve closing dynamics (average closing velocity and deceleration) immediately before valve closure. A high-fidelity, piezoelectric pressure transducer was mounted proximal to the mitral valve and measured the high-frequency pressure fluctuations caused by cavitation bubble formation and collapse after valve closure. The band-pass filtered root mean squared (RMS) value of the mitral pressure signal was used as a measure of cavitation intensity. The combination of these two techniques allowed the direct correlation of valve dynamics and cavitation intensity for each valve closure. The effects of three parameters on prosthetic heart valve dynamics and cavitation were examined: valve geometry (Medtronic Hall and Björk-Shiley Monostrut), occluder material (pyrolytic carbon and Delrin), and gap width between the occluder and housing. A dimensional analysis was also performed to investigate the general form of the relationship between valve dynamics and cavitation intensity. RESULTS: For all of the valves investigated in this study, the RMS pressure increased (signifying an increase in cavitation) as the average closing velocity and deceleration increased. In order to compare the cavitation potential of the valves, the RMS pressure was estimated at specific closing velocities using the linear regression of RMS pressure versus average closing velocity for each valve. The effects of valve geometry, occluder material and gap width were then examined at high valve loading conditions (closing velocity of 4.0 m/s). For both pyrolytic carbon and Delrin, the Medtronic Hall valves had significantly higher RMS pressures than did the Björk-Shiley Monostrut valves. For a given valve geometry, the pyrolytic carbon occluder had a significantly higher RMS pressure than the Delrin occluder. The valve gap width did not have a significant effect on RMS pressure. The dimensional analysis revealed the general relationship among average closing velocity, occluder material properties and cavitation intensity. CONCLUSIONS: The results presented here contribute to our fundamental understanding of cavitation on mechanical heart valves.

Heart Valve Prosthesis↗

PubMed1988

Experimental evaluation of the mitroflow pericardial heart valve prosthesis. Part II. Pathologic examination.

The results of the morphologic and histopathologic examination of 37 bovine pericardial heart valve prostheses that were retrieved after experimental implantation in Chacma baboons for periods of one to twelve months are presented in this study. The implanted prostheses consisted of 33 Mitroflow valves, size 21 mm, that belonged to four different groups according to the method of preparation of the pericardium (process I to IV) and 4 commercially available Ionescu-Shiley valves, size 19 mm. All implantations were in the mitral position, except 1 Mitroflow and 1 Ionescu-Shiley prosthesis, which were implanted in the tricuspid position. Moderate or abundant noninfected thrombotic deposits were found on the cusps of 13 of the 33 Mitroflow valves (39%). The Ionescu-Shiley valves shared this tendency, perhaps to a lesser extent, for the formation of thrombus on the valve cusps. Results of transmission electron microscopy, scanning electron microscopy, and calcification analysis are also presented. In this experimental study, the authors did not identify any significant characteristics in the Mitroflow bovine pericardial heart valve prosthesis that would lead to improved or extended durability of this device over the commercially available Ionescu-Shiley bovine pericardial heart valve prosthesis and probably over any other glutaraldehyde-treated bioprosthesis. They would suggest, therefore, that any clinical investigations of the prosthesis be undertaken very cautiously.

Animals↗

PubMed2000

Sarpogrelate reduces mechanical hemolysis in patients with heart valve prostheses.

OBJECTIVE: We evaluate the clinical efficacy of sarpogrelate, an antiplatelet drug that improves red blood cell deformability, to reduce the intravascular hemolysis problems suffered frequently by patients implanted with heart valve prostheses. SUBJECTS: Subjects were 34 patients undergoing mechanical heart valve replacement and having serum lactate dehydrogenase concentrations 20% above the maximum normal range. METHOD: Sarpogrelate was given daily, 100 mg orally for the first 6 months and 200 mg thereafter. RESULTS: Average serum lactate dehydrogenase decreased significantly from 423 +/- 108 IU/l, to 391 +/- 83 IU/l with the 100 mg dose, and to 361 +/- 86 IU/l with the 200 mg dose. The percentage of reticulocytes decreased from 15.5 +/- 5.3/1000 to 15.3 +/- 5.7/1000 at the 100 mg dose and 13.1 +/- 4.0/1000 at the 200 mg dose. Serum iron concentrations increased significantly from 63.2 +/- 24.8 micrograms/dl to 76.2 +/- 16.2 micrograms/dl at the 100 mg dose, and to 70.9 +/- 26.2 micrograms/dl with the 200 mg dose. CONCLUSION: Sarpogrelate is a useful drug for patients with implanted heart valve prostheses and subsequent high serum lactate dehydrogenase because it works as an antiplatelet drug and reduces mechanical hemolysis.

Adult↗